



# Biotech Daily

Thursday September 15, 2016

*Daily news on ASX-listed biotechnology companies*

- \* **ASX UP, BIOTECH DOWN: CLINUVEL UP 15%, COMPUMEDICS DOWN 12%**
- \* **RESAPP: 'UNNAMED ORGANIZATION TESTS RESPIRATORY DIAGNOSTIC'**
- \* **STUDY BACKS ANALYTICA PERICOACH FOR MS FAECAL INCONTINENCE**
- \* **AVIRAGEN (BIOTA) REVENUE DOWN 62% to \$13m, LOSS UP 33% TO \$34m**
- \* **BLUECHIIP, PLANET INNOVATION TRACKING DEVICE AGREEMENTS**
- \* **AUSTRALIAN ETHICAL REDUCES TO 10% OF INNATE**
- \* **INNATE DIRECTOR CHRISTOPHER COLLINS HOLDS 17%**
- \* **ALLAN GRAY INCREASES TO 13% OF STARPHARMA**
- \* **DORSAVI CTO DANIEL RONCHI BELOW 5%**

## MARKET REPORT

The Australian stock market was up 0.23 percent on Thursday September 15, 2016 with the ASX200 up 12.2 points to 5,239.9 points.

Thirteen of the Biotech Daily Top 40 companies were up, 16 fell, eight traded unchanged and three were untraded.

Clinuvel was the best, up 80 cents or 14.8 percent to \$6.20 with 34,244 shares traded.

Airxpanders climbed 9.7 percent; Benitec was up five percent; Actinogen and Universal Biosensors were up more than three percent; Factor Therapeutics, Nanosonics and Osprey rose more than two percent; Mesoblast, Pharmaxis and Viralytics were up more than one percent; with CSL, Pro Medicus and Sirtex up by less than one percent.

Compumedics led the falls, down seven cents or 11.8 percent to 52.5 cents with 534,325 shares traded.

Atcor lost 9.1 percent; Dimerix fell 5.9 percent; Acrux, Oncosil, Opthea and Prana shed more than four percent; Anteo, Bionomics, Cellmid and Neuren were down more than three percent; Living Cell shed 2.2 percent; Cochlear, Impedimed, Orthocell and Starpharma were down more than one percent; with Ellex and Resmed down by less than one percent.

## RESAPP HEALTH

Resapp says that with Uniquist it has shipped mobile telephones to an unnamed humanitarian organization to test its respiratory diagnostic in the developing world. Resapp said it had a non-binding memorandum of understanding with the organization to field-test the smartphone-based respiratory disease diagnostic.

The company said that pneumonia killed more than 950,000 children under five years every year, the majority in South Asia and sub-Saharan Africa, with many deaths caused by delays in diagnosis due to the lack of high-quality medical care in these regions.

Resapp said the evaluation was a precursor to a large-scale, multi-country study of the system's ability to accurately diagnose respiratory disease.

Resapp chief executive officer Dr Tony Keating said he was "excited to be working with this prestigious humanitarian organization to not only perform a field trial that will generate additional clinical evidence, but also to garner an in-depth understanding of the local conditions so that we can optimise a product for essential medical personnel working in very challenging environments".

Resapp was unchanged at 39 cents with three million shares traded.

## ANALYTICA

Analytica says a case study shows the clinical efficacy of its Pericoach intra-vaginal pelvic floor sensing technology for multiple sclerosis-related faecal incontinence.

Analytica said the study followed a 70-year-old female with multiple sclerosis and faecal incontinence using Pericoach as an adjunct treatment to her physical therapy sessions.

The company said that the study, entitled 'Pelvic Floor Muscle Strengthening Using Biofeedback for Treatment of Faecal Incontinence in a Patient with Multiple Sclerosis' was published in the Journal of Urology and Research and the article is available at:

<http://www.Pericoach.com/clinician/case-studies/>.

Analytica said that the study was authored by the Denver, Colorado-based physical therapist Dawn Sandalcidi, a member of the company's US clinical advisory board.

"This was a tough case," Ms Sandalcidi said. "I had a 70-year-old woman who had undergone two surgeries to repair rectal prolapse, yet was still suffering with symptoms which included faecal incontinence."

"Multiple sclerosis results in reduced muscle control making it difficult to strengthen muscle," Ms Sandalcidi said.

"In particular the pelvic floor muscles are more challenging to retrain without feedback," Ms Sandalcidi said.

"The Pericoach biofeedback and the smartphone [application] provided guidance for neuromuscular re-education in between physical therapy visits," Ms Sandalcidi said.

"We saw her improve from limited pelvic floor strength and control to a functioning pelvic floor in 12 weeks," Ms Sandalcidi said.

"The support of the complete Pericoach system, smart phone app and portal, provided the reassurance and motivation I needed to keep this women committed to her treatment course," Ms Sandalcidi said.

Analytica said that its Pericoach had been cleared by the US Food and Drug Administration for the treatment of urinary incontinence through the strengthening of pelvic floor muscles.

The company said that a weak pelvic floor could contribute to other conditions including uterine prolapse, rectal prolapse, faecal incontinence, sexual dysfunction, lower back pain and supra-pubic pain.

Analytica was up 0.1 cents or 16.7 percent to 0.7 cents with 6.6 million shares traded.

### AVIRAGEN THERAPEUTICS (FORMERLY BIOTA PHARMACEUTICALS)

Aviragen says that revenue for the year to June 30, 2016 fell 62.2 percent to \$US9.3 million (\$A12.5 million) with net loss after tax up 33.0 percent to \$US25.4 million (\$A34.0 million).

Aviragen said it had “strengthened our balance sheet with \$US20 million of non-dilutive cash from the partial monetization of our Inavir royalty stream” (BD: Apr 26, 2016).

The company said the \$US6.3 million increased loss was primarily due to a \$US15.5 million decrease in revenues reflecting a \$US7.0 million reduction in royalty revenue, principally related to Relenza, and \$US8.5 million in lower service revenue, due to the cancellation of the BARDA contract in 2014 (BD Apr 30, May 1, 9, 2014).

Aviragen said that the net loss was impacted by a \$US6.5 million increase in research and development expense, primarily the vapendavir and BTA585 clinical programs.

The company said that diluted loss per share increased 22.2 percent to 66 US cents at June 30, 2016 and it had cash and cash equivalents of \$US49.7 million at June 30, 2016, compared to \$US44.7 million at June 30, 2015.

Last night on the Nasdaq, Aviragen was up one US cent or 0.71 percent to \$US1.42 (\$A1.90, equivalent to 23.8 cents before the Biota and Nabi merger, when it was trading at \$1.00 a share) with 84,974 shares traded.

### BLUECHIIP

Bluechiip says it has a non-exclusive licence, supply agreement and master services agreement with the Melbourne-based Planet Innovation.

Bluechiip said that Planet Innovation developed and commercialized products that had “a positive impact on the world”, providing technology innovation, product development and commercialization expertise to companies, primarily in the bio-medical and high technology industries.

Bluechiip chief executive officer Andrew McLellan said the announcement “crystallizes a relationship that has grown over the last year”.

“This will allow [Bluechiip] and its technology to be more rapidly adapted both for our growing pipeline of opportunities and for the partners we already have in place,” Mr McLellan said.

Bluechiip said that the parties would jointly pursue projects where Planet Innovation’s capabilities would be used to create products that integrated its wireless tracking technology and it would gain access to Planet Innovation’s customer network in the medical devices market.

The company said that it had granted a non-exclusive licence to Planet Innovation to develop products that integrated its technology in the field of systems and devices for the handling, storage or monitoring of medical or biological products or samples, excluding assisted reproductive technologies where it had an agreement with Genea Biomedx.

Bluechiip said it would provide its technology to Planet Innovation including tags, readers and software and Planet Innovation had committed to minimum annual development expenditure, alternatively to minimum annual purchasing obligations.

The company said that under the master service agreement Bluechiip had granted a non-exclusive license to Planet Innovation to develop products that integrate Bluechiip’s technology and sell those newly developed products along with a mutual right for each party to engage the other to develop technology for and on behalf of the other, while Bluechiip retained all rights to its core technology and intellectual property.

Bluechiip was untraded at 2.4 cents.

### INNATE IMMUNOTHERAPEUTICS

Australian Ethical Investment says it has reduced its substantial shareholding in Innate from 23,064,739 shares (11.06%) to 21,380,718 shares (9.66%).

Australian Ethical said that between July 22 and September 12, 2016 it sold 1,684,021 shares with the largest sale 280,000 shares for \$156,739 or 56 cents a share.

In July, Australian Ethical said it bought and sold shares between January 15, 2014 and July 18, 2016 with the largest acquisitions 4,503,867 shares for \$1,125,967 or 25 cents a share (BD: Jul 21, 2016).

Innate was up one cent or 1.9 percent to 53 cents.

### INNATE IMMUNOTHERAPEUTICS

Innate director Christopher Collins says he has increased his holding from 33,899,139 shares to 37,899,139 shares but has been diluted 0.14 percent to 17.12 percent.

Mr Collins said he acquired 4,000,000 shares for \$1,000,000 or 25 cents a share in the July placement which raised \$6,626,610 (BD: Jun 10, Jul 20, 2016).

### STARPHARMA HOLDINGS

Allan Gray Australia says it has increased its holding in Starpharma from 44,662,525 shares (12.26%) to 49,041,042 shares (13.36%).

Allan Gray said that between March 29 and September 12, 2016 it bought and sold shares with the single largest purchase 2,241,042 shares for \$1,517,597 or 67.7 cents a share.

Starpharma fell one cent or 1.5 percent to 67 cents.

### DORSAVI

Dorsavi chief technology officer Daniel Ronchi says he has reduced his holding in the company by 990,000 shares to below the five percent substantial shareholder mark.

Mr Ronchi said that the shares were held by DR BSM Pty Ltd as trustee for the DR BSM Trust and were sold for \$356,400 or 36 cents a share "as a result of a process of matrimonial property settlement".

Dorsavi was up half a cent or 1.1 percent to 46 cents.